CBP501
Drug Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | CBP501 |
| Trade Name | |
| Synonyms | CBP-501|CBP 501 |
| Drug Descriptions |
CBP501 is a peptide drug that inhibits the activity of several kinases responsible for phosphorylation of CDC25C, including MAPKAP-K2, C-Tak1, and CHK1, resulting in disruption of the G2 checkpoint and potentially leading to cell-cycle arrest and increased tumor cell death (PMID: 17237275, PMID: 29088764). |
| DrugClasses | CHK1 Inhibitor 18 |
| CAS Registry Number | 565434-85-7 |
| NCIT ID | C71529 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Bleomycin + CBP501 | Bleomycin CBP501 | 0 | 0 |
| CBP501 | CBP501 | 0 | 0 |
| CBP501 + Cisplatin | CBP501 Cisplatin | 0 | 1 |
| CBP501 + Cisplatin + Nivolumab | CBP501 Cisplatin Nivolumab | 0 | 2 |
CKB BOOST